rediff.com
REAL-TIME QUOTE
Enter Company or MF
e.g. Tata motors, Reliance MF, 500570
DIVI'S LABORATORIES LTD. - Updates
Download announcement < Back
22 Apr 2017
Further to our earlier communication dated 8th April, 2017 to the Stock Exchanges, we wish to update that the US-FDA has issued a Warning Letter for the company&apos;s Unit-II at Visakhapatnam. Divi&apos;s Laboratories responded to the US-FDA inspection observations with an appropriate remediation process to overcome the deficiencies observed. As part of our commitments, we have also provided periodic updates to the US-FDA. In the Import Alert issued, US-FDA has exempted several products manufactured at the company&apos;s Unit-II at Visakhapatnam, Andhra Pradesh. We will continue to supply these active ingredients to meet its obligations to our customers. Divi&apos;s Labs, along with external consultants and subject matter experts, are working to address the concerns of the US-FDA and is making all efforts to fully meet the compliance requirements. We will respond to this Warning Letter with a detailed plan within the stipulated time.
View all announcements for DIVI'S LABORATORIES LTD. Source: BSE India